Post by Simon-Kucher

Orphan status no longer guarantees pricing and reimbursement success. As payer scrutiny increases and competition intensifies, manufacturers need stronger evidence strategies to support access, differentiation, and long-term value. Explore how real world evidence can help address four critical challenges in the process: skp.link/tcda #BetterMarketAccess #Pharma #OrphanDrugs #RWE #EvidenceStrategy